

# Senseonics Announces Appointment of Francine R. Kaufman, M.D. as Chief Medical Officer



March 06, 2019

GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the appointment of Francine R. Kaufman, M.D. as Chief Medical Officer, effective immediately.

“We are pleased to have Fran join the executive leadership team at Senseonics. As Chief Medical Officer, she will be instrumental in helping drive forward our innovation platform and the clinical value proposition of the Eversense system,” said Tim Goodnow, President and CEO of Senseonics. “Fran is one of the world’s leading endocrinologists and her deep understanding of the global medical, research, and clinical diabetes community coupled with her track record of applying novel technologies to advance diabetes care for patients make her ideally suited for the role. We are confident that with her leadership, we will further transform and elevate the Eversense platform and bolster our US commercialization efforts at this critical point.”

Dr. Kaufman’s career spans almost 40 years in diabetes care. She is a dedicated pediatric endocrinologist and has served as director of the Comprehensive Childhood Diabetes Center, and head of the Center for Endocrinology, Diabetes and Metabolism at Children’s Hospital Los Angeles. Dr. Kaufman is also a Distinguished Professor Emerita of Pediatrics and Communications at the Keck School of Medicine and the Annenberg School of Communications of the University of Southern California. She was formerly the president of the American Diabetes Association, chair of the National Diabetes Education Program and elected to the National Academy of Medicine. She is the author of over 250 scientific manuscripts and numerous books, including *Diabetes: The Obesity-Diabetes Epidemic That Threatens America* and the *ADA’s Insulin Pumps and Continuous Glucose Monitoring: A User’s Guide to Effective Diabetes Management*. Dr. Kaufman is an active philanthropist working with numerous organizations and charities around the world aimed at improving the lives of people with diabetes. She was also an advisor to the Governor on the California Initiative on Health, Fitness and Obesity. Most recently Dr. Kaufman served as Chief Medical Officer and Vice President of Global Clinical, Regulatory and Medical Affairs at

Medtronic Diabetes. She received a Bachelor of Arts degree from Northwestern University and was the Valedictorian of her class at Chicago Medical School.

“I am very excited to join the Senseonics team, especially at this point where I feel I have an opportunity to help lay the foundation for the first long-term implantable continuous glucose monitoring system,” said Dr. Kaufman. “I have spent my career exploring the treatment and management of diabetes to improve outcomes for patients. I believe in the clinical value the Eversense system provides and am eager to help patients and providers realize its benefits.”

## **About Senseonics**

Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of transformational glucose monitoring products designed to help people with diabetes confidently live their lives with ease. Senseonics' CGM systems, Eversense<sup>®</sup> and Eversense<sup>®</sup> XL, include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data is automatically sent every 5 minutes to a mobile app on the user's smartphone.

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20190306005258/en/>

## **Senseonics Investor Relations Contact:**

Lynn Lewis or Philip Taylor

Investor Relations

415-937-5406

[Investors@senseonics.com](mailto:Investors@senseonics.com)

## **Media Contact:**

SignalWest Public Relations

Jeff Christensen, 831-566-0275

[jeff@signalwestpr.com](mailto:jeff@signalwestpr.com)

Source: Senseonics Holdings, Inc.